Insider Trading
Current insider transactions (SEC Form 4) — buys and sells by officers, directors, and major shareholders.
| Ticker | Insider | Title | Date | Transaction | Price ($) | Shares | Value ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SHOO | Ferrara Al | Director | 08/04/2026 | Verkauf | 48.26 | 3,918 | 189,083 | Form 4 |
| SHOO | Davis Peter Allan | Director | 08/04/2026 | Verkauf | 48.31 | 525 | 25,360 | Form 4 |
| SMBK | Jordan Rhett D. | EVP & CHIEF CREDIT OFFICER | 08/04/2026 | Verkauf | 52.75 | 430 | 22,683 | Form 4 |
| SKYX | Barron Patricia Ann | Chief Operations Officer | 08/04/2026 | Steuer-Abgabe | 1.11 | 8,410 | 9,335 | Form 4 |
| SMHI | Everett Andrew H II | Sr. VP, General Counsel & Secy | 08/04/2026 | Verkauf | 9.56 | 1,018 | 9,732 | Form 4 |
| SBCF | Shaffer Charles M | Chairman, President & CEO | 08/04/2026 | Steuer-Abgabe | 35.47 | 25,851 | 916,935 | Form 4 |
| SBCF | Shaffer Charles M | Chairman, President & CEO | 08/04/2026 | Optionsausübung | 28.69 | 28,544 | 818,927 | Form 4 |
| SCHW | Schwab Charles R. | Co-Chairman | 08/04/2026 | Verkauf | 106.08 | 47,650 | 5,054,569 | Form 4 |
| STOK | Ticho Barry | CHIEF MEDICAL OFFICER | 08/03/2026 | Verkauf | 29.45 | 1,269 | 37,377 | Form 4 |
| STOK | Ticho Barry | CHIEF MEDICAL OFFICER | 08/03/2026 | Verkauf | 28.95 | 5,907 | 171,008 | Form 4 |
| SFIX | Bacos Anthony | Chief Prod/Technology Officer | 08/03/2026 | Verkauf | 4.09 | 20,000 | 81,722 | Form 4 |
| SFIX | Bacos Anthony | Chief Prod/Technology Officer | 08/03/2026 | Verkauf | 4.09 | 50,000 | 204,355 | Form 4 |
| SFIX | Bacos Anthony | Chief Prod/Technology Officer | 08/03/2026 | Optionsausübung | 2.48 | 50,000 | 124,000 | Form 4 |
| SARO | Ford Russell Wayne | Chief Executive Officer | 08/03/2026 | Verkauf | 30.04 | 10,969 | 329,501 | Form 4 |
| SYRE | Burrows Scott L | Chief Financial Officer | 08/03/2026 | Verkauf | 97.10 | 100 | 9,710 | Form 4 |
| SYRE | Burrows Scott L | Chief Financial Officer | 08/03/2026 | Verkauf | 96.30 | 2,300 | 221,490 | Form 4 |
| SYRE | Burrows Scott L | Chief Financial Officer | 08/03/2026 | Verkauf | 95.21 | 5,100 | 485,571 | Form 4 |
| SYRE | Burrows Scott L | Chief Financial Officer | 08/03/2026 | Optionsausübung | 14.50 | 7,500 | 108,750 | Form 4 |
| SYRE | Turtle Cameron | Chief Executive Officer | 08/03/2026 | Verkauf | 97.46 | 16 | 1,559 | Form 4 |
| SYRE | Turtle Cameron | Chief Executive Officer | 08/03/2026 | Verkauf | 96.82 | 1,392 | 134,773 | Form 4 |
| SYRE | Turtle Cameron | Chief Executive Officer | 08/03/2026 | Verkauf | 95.93 | 5,635 | 540,566 | Form 4 |
| SYRE | Turtle Cameron | Chief Executive Officer | 08/03/2026 | Verkauf | 95.10 | 7,157 | 680,631 | Form 4 |
| SYRE | Turtle Cameron | Chief Executive Officer | 08/03/2026 | Verkauf | 93.97 | 800 | 75,176 | Form 4 |
| SFM | Sinclair Jack | Chief Executive Officer | 08/03/2026 | Verkauf | 89.34 | 10,788 | 963,757 | Form 4 |
| SFM | Sinclair Jack | Chief Executive Officer | 08/03/2026 | Optionsausübung | 16.47 | 10,788 | 177,678 | Form 4 |
| SPT | Rankin Aaron Edward Frederick | Chief Technology Officer | 08/03/2026 | Zuteilung | — | 120,192 | — | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 506.04 | 315 | 159,404 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 503.86 | 254 | 127,979 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 502.86 | 1,159 | 582,812 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 502.05 | 1,865 | 936,314 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 501.16 | 1,253 | 627,951 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 499.96 | 590 | 294,975 | Form 4 |
| SPOT | Norstrom Alex | Co-Chief Executive Officer | 08/03/2026 | Optionsausübung | 151.25 | 5,436 | 822,195 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 511.64 | 706 | 361,218 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 510.94 | 4,089 | 2,089,223 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 510.00 | 2,235 | 1,139,844 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 508.99 | 2,377 | 1,209,878 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 508.19 | 2,224 | 1,130,210 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 506.87 | 2,054 | 1,041,112 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 506.04 | 1,553 | 785,878 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 504.76 | 242 | 122,152 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 504.03 | 600 | 302,419 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 502.90 | 1,574 | 791,570 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 502.07 | 1,666 | 836,444 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 501.17 | 744 | 372,869 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Verkauf | 500.03 | 769 | 384,520 | Form 4 |
| SPOT | Soderstrom Gustav | Co-Chief Executive Officer | 08/03/2026 | Optionsausübung | 151.25 | 20,833 | 3,150,991 | Form 4 |
| SPIR | Mellinger Eric M. | Chief Commercial Officer | 08/03/2026 | Zuteilung | — | 150,000 | — | Form 4 |
| SNOW | Kleinerman Christian | EVP, Product Management | 08/03/2026 | Verkauf | 300.00 | 5,000 | 1,500,000 | Form 4 |
| SLDE | Gries Robert JR | Director | 08/03/2026 | Verkauf | 20.33 | 28,212 | 573,550 | Form 4 |
| SEPN | Long Daniel D. | SVP, Drug Discovery | 08/03/2026 | Verkauf | 34.68 | 2,334 | 80,944 | Form 4 |
| SEPN | Long Daniel D. | SVP, Drug Discovery | 08/03/2026 | Verkauf | 33.98 | 1,000 | 33,976 | Form 4 |
| SEPN | Long Daniel D. | SVP, Drug Discovery | 08/03/2026 | Optionsausübung | 2.76 | 1,518 | 4,190 | Form 4 |
| SEPN | Long Daniel D. | SVP, Drug Discovery | 08/03/2026 | Optionsausübung | 2.76 | 1,816 | 5,012 | Form 4 |
| SNDR | Rourke Mark B. | Executive Chair | 08/03/2026 | Verkauf | 35.18 | 20,312 | 714,503 | Form 4 |
| SNDR | Rourke Mark B. | Executive Chair | 08/03/2026 | Optionsausübung | 24.81 | 20,312 | 503,941 | Form 4 |
| SPFI | Campbell Richard D | Director | 08/03/2026 | Verkauf | 44.75 | 132,714 | 5,938,952 | Form 4 |
| SKYW | Steel Wade J | CHIEF COMMERCIAL OFFICER | 08/03/2026 | Verkauf | 111.44 | 22,000 | 2,451,676 | Form 4 |
| SIBN | Dunn Jeffrey W | Director | 08/03/2026 | Verkauf | 18.46 | 20,000 | 369,214 | Form 4 |
| SIBN | Dunn Jeffrey W | Director | 08/03/2026 | Optionsausübung | 4.68 | 20,000 | 93,600 | Form 4 |
A compact market overview — not investment advice. Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q).